The real retatrutide before and after is a measured one: 24.2% mean body-weight loss at 48 weeks on 12 mg, against 2.1% on placebo. The photos you'll find are impossible to verify. A photo shows one person at two moments, and it can't tell you how likely that result was.
The honest retatrutide before-and-after is a dataset, not a photograph. At 48 weeks, the 12 mg arm averaged a 24.2% reduction in body weight, versus 2.1% on placebo. In that arm, 83% of participants lost at least 15% of their body weight. That distribution, including the people at the bottom of it, is more informative than any image pair.
Before-and-after imagery is the worst evidence in this category and the most abundant. There's no baseline control, and no verification that the person took what they say they took at the dose they claim.
There's also no way to separate the drug from everything else that changed, and heavy selection pressure toward the people it worked best for. Nobody posts the photo where nothing happened.
Trial data does something the photos structurally can't. It reports the whole distribution, including the tail.
What the trial reported
Jastreboff and colleagues randomized 338 adults with obesity across five retatrutide arms and placebo, dosed once weekly for 48 weeks. Mean body-weight change at week 48:
| Arm | Mean weight change | Versus placebo |
|---|---|---|
| Placebo | −2.1% | — |
| 1 mg | −8.7% | −6.6 pts |
| 4 mg | −17.1% | −15.0 pts |
| 8 mg | −22.8% | −20.7 pts |
| 12 mg | −24.2% | −22.1 pts |
At time of publication, that 24.2% was the largest mean body-weight reduction documented for any pharmaceutical agent. It sits closer to bariatric-surgery territory than to anything else in a pill or a syringe.
The part photos never show: the spread
Threshold-response data is where individual variation becomes visible. On the 12 mg arm:
- 100% of participants lost at least 5% of body weight (versus 27% on placebo)
- 93% lost at least 10% (versus 9%)
- 83% lost at least 15% (versus 2%)
Two readings of that are both correct. It's a remarkably consistent response, because nearly everyone in the top-dose arm lost clinically meaningful weight. It's also still a distribution: roughly one in six people on the highest dose didn't reach 15%.
A before-and-after photo is a single draw from that distribution, chosen by someone with a reason to pick the best one.
A photograph reports one draw from the distribution. The trial reports the distribution, including the sixth person who didn’t reach 15%.
— WTBP Research Team note, 2026
Expect the Phase 3 number to be lower. Phase 2 trials over-report efficacy relative to Phase 3 as a matter of structure, not fraud. Smaller samples, more adherence support at sites, and selection effects that favor responders all push the same way.
We'd expect TRIUMPH to regress into the 18–22% range. That would still be the best result in the class. It just wouldn't be 24.2%.
What the timeline looked like
Participants titrated to target dose over roughly the first 12 weeks. So the first quarter of the trial was spent getting to the dose rather than sitting at it.
The weight curve through 48 weeks hadn't plateaued when the study ended. Nobody knows where it goes at 72 or 96 weeks, because no published trial has run that long. Our dosing protocol page covers how the escalation was structured.
GLP3-R (retatrutide)
The triple-agonist reference compound used across the Jastreboff Phase 2 literature. Research use only — supplied with a batch-matched certificate of analysis.
The question the photos definitely don't answer
What happens when you stop. No published retatrutide withdrawal trial exists, but the class has an answer and it isn't encouraging.
Tirzepatide's SURMOUNT-4 maintenance trial found that discontinuation produced major weight regain. That's what reframed the drug as chronic therapy rather than a course of treatment, and we can't see a mechanistic reason retatrutide would behave differently.
A before-and-after pair captures a moment inside a treatment period. It tells you nothing about the year after it.
For how retatrutide's numbers sit against the rest of the class, see retatrutide vs tirzepatide and the 2026 GLP-1 class comparison.
Frequently asked questions
What weight loss did retatrutide produce in the trial?
At 48 weeks, mean body-weight reduction was 24.2% on the 12 mg dose, 22.8% at 8 mg, 17.1% at 4 mg and 8.7% at 1 mg, against 2.1% on placebo. On the 12 mg dose, 83% of participants lost at least 15% of body weight.
How long does retatrutide take to work?
The trial ran 48 weeks and the weight curve had not plateaued at the end of it. Participants also spent the first ~12 weeks titrating up to target dose, so the steepest part of the response came after that window rather than in the first month.
Are retatrutide before-and-after photos reliable?
Photographs are the least reliable evidence in this category. There's no baseline control, no verification the person took what they claim, and heavy selection for the best responders. The trial's threshold-response data tells you far more, because it reports what share of participants hit each weight-loss threshold, including the ones who did poorly.
Does the weight come back if you stop?
In tirzepatide's SURMOUNT-4 maintenance trial, discontinuation produced major weight regain, which reframed that drug as chronic therapy rather than a course. No equivalent retatrutide withdrawal trial has been published, and we can't see a mechanistic reason it would behave differently.
What we’re watching
TRIUMPH is the readout that matters. It's the Phase 3 program, and it will report a mean weight change in a larger, less hand-held population than the Phase 2 trial did.
We're also watching for a maintenance arm. Until somebody runs a retatrutide withdrawal trial, the regain question is answered by borrowing tirzepatide's data, and that's a borrowed answer rather than a measured one.
GLP3-R (retatrutide)
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- At 48 weeks the 12 mg arm averaged a 24.2% reduction in body weight.
- Placebo in the same trial averaged 2.1%, the comparison a photograph never includes.
- 83% of participants in that arm lost at least 15% of their body weight.
- That leaves a minority who did not reach the threshold, and the spread matters as much as the mean.
- The distribution, including the people at the bottom of it, is more informative than any pair of images.
References
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y
Threshold-response percentages are from the Phase 2 publication. The weight-regain finding is from tirzepatide's SURMOUNT-4 maintenance trial — no equivalent retatrutide withdrawal trial has reported.